Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
NCT ID: NCT07135856
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
400 participants
OBSERVATIONAL
2025-09-01
2026-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Does minimally invasive sleeve lobectomy result in comparable or improved perioperative and postoperative outcomes compared to open thoracotomy following neoadjuvant treatment in NSCLC?
* Does surgical approach influence oncologic endpoints such as margin status, lymph node dissection, recurrence-free survival, and overall survival? This research addresses a critical gap in the thoracic oncology field by evaluating the safety, complexity, and efficacy of advanced surgical techniques in the context of evolving multimodal therapy paradigm. Findings may inform clinical decision-making and optimize patient selection in an era of increasing use of neoadjuvant strategies for resectable NSCLC.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Thoracotomy sleeve lobectomy
Patients who underwent open sleeve lobectomy following neoadjuvant therapy
No interventions assigned to this group
MIS sleeve lobectomy
Patients who underwent minimally invasive (i.e. VATS and RATS) sleeve lobectomy following neoadjuvant therapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed NSCLC
* Undergoing sleeve lobectomy with curative intent
* Receipt of neoadjuvant therapy (chemotherapy, immunotherapy, target therapy, etc.)
* Surgical approach: either minimally invasive (VATS or RATS) or open thoracotomy
* Availability of complete perioperative and follow-up data (minimum 12-month follow-up or until death)
* Signed informative consent
Exclusion Criteria
* Absence of neoadjuvant therapy
* Purely diagnostic surgical procedures
* Incomplete medical records or lost to follow-up
* Metastatic (stage IV) disease at time of surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sir Run Run Shaw Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
University of Padova, Padova, Italy
UNKNOWN
Shanghai Chest Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xinghua Cheng
Director, Head of Oncology Surgery, Clinical Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xinghua Cheng, M.D., Ph.D.
Role: primary
Zhebing Lin, M.D.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ShanghaiChestNeoSleeve
Identifier Type: -
Identifier Source: org_study_id